Major institutional moves, such as Soros Fund Management cutting its stake by nearly 16% in late 2025, signal a lack of confidence in a quick turnaround. The Bull Case: Deep Value and Long-Term Recovery
Humana Inc. (HUM) is currently navigating a period of significant transition as of late April 2026. While its stock has faced immense pressure—trading around , down from year-ago highs of approximately $315 —the investment case for Humana is a complex tug-of-war between immediate structural headwinds and a long-term recovery thesis. The Bear Case: Structural Pressures in 2026 humana stock buy or sell
Humana ’s 2026 adjusted earnings per share (EPS) guidance of "at least $9.00" represents a massive drop from the $17.14 earned in 2025. This is largely due to a projected $3.5 billion headwind from reduced government bonus payments tied to those star ratings. Major institutional moves, such as Soros Fund Management
The company’s net profit margin sat at a razor-thin 0.92% at the end of 2025. Rising medical utilization and relatively flat government reimbursement rates continue to squeeze profitability. While its stock has faced immense pressure—trading around
Contrarian investors argue that the current price reflects "peak pessimism" and offers a generational entry point.
The primary catalyst for recent stock declines is a "gut punch" from lower .